Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease

Mark D. DeBoer, Daniel Marks

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia both worsens quality of life and negatively affects treatment of the underlying disease. Conditions as diverse as cancer, renal failure, and heart failure show a remarkable similarity in their associated cachexia, exhibiting changes in metabolism and endocrinology, including marked increases in levels of cytokines that accompany these diseases. So far, it has been difficult to treat disease-associated cachexia successfully. One treatment that has shown promise in animal trials, however, involves antagonism of the central melanocortin system, an anorexigenic pathway in the hypothalamus and brainstem. Humans who have genetic mutations involving pro-opiomelanocortin or the melanocortin 4 receptor in this pathway exhibit increased appetite and increased lean body mass. Recent research has shown that in rodent models of cancer and renal failure, administration of melanocortin 4 receptor antagonists results in an attenuation of symptoms of cachexia, including maintenance of appetite, lean body mass, and basal energy expenditure. Although this research needs to be substantiated in humans, it provides a promising direction for treating the wasting that is associated with a variety of disease states.

Original languageEnglish (US)
Pages (from-to)459-466
Number of pages8
JournalNature Clinical Practice Endocrinology and Metabolism
Volume2
Issue number8
DOIs
StatePublished - Aug 25 2006

Fingerprint

Melanocortins
Cachexia
Chronic Disease
Appetite
Receptor, Melanocortin, Type 4
Energy Metabolism
Renal Insufficiency
Therapeutics
Pro-Opiomelanocortin
Endocrinology
Research
Hypothalamus
Brain Stem
Rodentia
Neoplasms
Heart Failure
Maintenance
Quality of Life
Cytokines
Mutation

Keywords

  • Appetite
  • Cachexia
  • Cytokines
  • Inflammation
  • Pro-opiomelanocortin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Therapy insight : Use of melanocortin antagonists in the treatment of cachexia in chronic disease. / DeBoer, Mark D.; Marks, Daniel.

In: Nature Clinical Practice Endocrinology and Metabolism, Vol. 2, No. 8, 25.08.2006, p. 459-466.

Research output: Contribution to journalArticle

@article{0409eed8ecc546ae9793d73aea861d7d,
title = "Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease",
abstract = "Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia both worsens quality of life and negatively affects treatment of the underlying disease. Conditions as diverse as cancer, renal failure, and heart failure show a remarkable similarity in their associated cachexia, exhibiting changes in metabolism and endocrinology, including marked increases in levels of cytokines that accompany these diseases. So far, it has been difficult to treat disease-associated cachexia successfully. One treatment that has shown promise in animal trials, however, involves antagonism of the central melanocortin system, an anorexigenic pathway in the hypothalamus and brainstem. Humans who have genetic mutations involving pro-opiomelanocortin or the melanocortin 4 receptor in this pathway exhibit increased appetite and increased lean body mass. Recent research has shown that in rodent models of cancer and renal failure, administration of melanocortin 4 receptor antagonists results in an attenuation of symptoms of cachexia, including maintenance of appetite, lean body mass, and basal energy expenditure. Although this research needs to be substantiated in humans, it provides a promising direction for treating the wasting that is associated with a variety of disease states.",
keywords = "Appetite, Cachexia, Cytokines, Inflammation, Pro-opiomelanocortin",
author = "DeBoer, {Mark D.} and Daniel Marks",
year = "2006",
month = "8",
day = "25",
doi = "10.1038/ncpendmet0221",
language = "English (US)",
volume = "2",
pages = "459--466",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Therapy insight

T2 - Use of melanocortin antagonists in the treatment of cachexia in chronic disease

AU - DeBoer, Mark D.

AU - Marks, Daniel

PY - 2006/8/25

Y1 - 2006/8/25

N2 - Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia both worsens quality of life and negatively affects treatment of the underlying disease. Conditions as diverse as cancer, renal failure, and heart failure show a remarkable similarity in their associated cachexia, exhibiting changes in metabolism and endocrinology, including marked increases in levels of cytokines that accompany these diseases. So far, it has been difficult to treat disease-associated cachexia successfully. One treatment that has shown promise in animal trials, however, involves antagonism of the central melanocortin system, an anorexigenic pathway in the hypothalamus and brainstem. Humans who have genetic mutations involving pro-opiomelanocortin or the melanocortin 4 receptor in this pathway exhibit increased appetite and increased lean body mass. Recent research has shown that in rodent models of cancer and renal failure, administration of melanocortin 4 receptor antagonists results in an attenuation of symptoms of cachexia, including maintenance of appetite, lean body mass, and basal energy expenditure. Although this research needs to be substantiated in humans, it provides a promising direction for treating the wasting that is associated with a variety of disease states.

AB - Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia both worsens quality of life and negatively affects treatment of the underlying disease. Conditions as diverse as cancer, renal failure, and heart failure show a remarkable similarity in their associated cachexia, exhibiting changes in metabolism and endocrinology, including marked increases in levels of cytokines that accompany these diseases. So far, it has been difficult to treat disease-associated cachexia successfully. One treatment that has shown promise in animal trials, however, involves antagonism of the central melanocortin system, an anorexigenic pathway in the hypothalamus and brainstem. Humans who have genetic mutations involving pro-opiomelanocortin or the melanocortin 4 receptor in this pathway exhibit increased appetite and increased lean body mass. Recent research has shown that in rodent models of cancer and renal failure, administration of melanocortin 4 receptor antagonists results in an attenuation of symptoms of cachexia, including maintenance of appetite, lean body mass, and basal energy expenditure. Although this research needs to be substantiated in humans, it provides a promising direction for treating the wasting that is associated with a variety of disease states.

KW - Appetite

KW - Cachexia

KW - Cytokines

KW - Inflammation

KW - Pro-opiomelanocortin

UR - http://www.scopus.com/inward/record.url?scp=33747054431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747054431&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet0221

DO - 10.1038/ncpendmet0221

M3 - Article

C2 - 16932335

AN - SCOPUS:33747054431

VL - 2

SP - 459

EP - 466

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 8

ER -